projects:workgroups:transfusion
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Last revision Both sides next revision | ||
|
projects:workgroups:transfusion [2019/12/02 13:57] cgreich |
projects:workgroups:transfusion [2019/12/13 02:45] cgreich |
||
|---|---|---|---|
| Line 7: | Line 7: | ||
| Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. | Transfusions are special treatments which are currently in active research by the FDA BEST and the [[https://www.nhlbi.nih.gov/science/recipient-epidemiology-and-donor-evaluation-study-reds-program|REDS-IV]] program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap. | ||
| - | * [[documentation:transfusion:Data_Source|Use Cases]] | + | == Use Cases == |
| - | * Modelling Isues: | + | * Effect of number of units on outcomes |
| - | * Detailed facts about transfused units, such as | + | * Effect of single donor vs pooled on outcomes |
| + | * Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes | ||
| + | * Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others | ||
| + | * Fatality rates of outcomes | ||
| + | * Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood | ||
| + | * Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction | ||
| + | * Incidence rates of outcomes by indication and associated procedures and other possible risk factors | ||
| + | * Incidence rates of outcomes by donor characteristics | ||
| + | |||
| + | == Modelling Issues == | ||
| + | |||
| + | * Detailed facts about transfused units, such as | ||
| + | * Manipulation: cultured enrichment, demineralization, genetical modification, | ||
| + | * Concentration, dosage, portioning and unit of issue, | ||
| + | * Preservation: irradiation and pathogen reduction, transport, storage, cryoprotection, | ||
| + | * monitoring: preparation, processing, mobilization, modification, quarantine, | ||
| + | * Additive, excipient and nutrient content | ||
| + | * Dose | ||
| + | * Units | ||
| + | * Route | ||
| + | * Start/End Time | ||
| + | * Multiple touch points of interest (prescribe/dispense/admin) | ||
| + | * Lab results specific to the unit for unit-specific data (product CD34+ vs patient CD34+) | ||
| * [[projects:workgroups:transfusion:members|Participants]] | * [[projects:workgroups:transfusion:members|Participants]] | ||
projects/workgroups/transfusion.txt · Last modified: 2019/12/13 04:05 by cgreich
Page Tools
